GlassScriptPhysician profile
Mark Logan Hill
NPI 1386871838
$4,418.89
in general payments reported to CMS, 2019-2025
25 companies · $866 in 2025
The $866 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $270 · 2021: $344 · 2022: $1,029 · 2023: $827 · 2024: $798 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,433.99 | 2022-2025 | |
| Alcon Vision LLC | $749.75 | 2019-2025 | Clareon, Argos, Tryptyr |
| Ocular Therapeutix, INC. | $417.78 | 2021-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $245.64 | 2019-2023 | |
| Genentech USA, INC. | $204.11 | 2022-2024 | Vabysmo, Lucentis |
| Oyster Point Pharma, INC. | $147.81 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $146.22 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $118.84 | 2019-2021 | |
| Glaukos Corporation | $117.31 | 2020-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $113.31 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $111.60 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $102.08 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $90.28 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $80.59 | 2019 | |
| Rxsight INC | $67.63 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $51.16 | 2024 | |
| Kala Pharmaceuticals, INC. | $38.15 | 2021 | |
| Dompe US, INC. | $33.14 | 2025 | Oxervate |
| Lensar, INC. | $31.60 | 2023 | Lensar Laser System |
| Harrow Eye, LLC | $27.46 | 2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $25.99 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $20.46 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Ani Pharmaceuticals, INC. | $16.39 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $14.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.